{"id":40290,"date":"2001-03-01T12:05:00","date_gmt":"2001-03-01T11:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie"},"modified":"2001-03-01T12:05:00","modified_gmt":"2001-03-01T11:05:00","slug":"eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/","title":{"rendered":"Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie"},"content":{"rendered":"<p>Unmittelbar vor und 3-4 Wochen nach einer koronaren Ballondilatation (Perkutane transluminale koronare Angioplastie = PTCA) mit Stent-Implantation wird heute eine Pharmakotherapie mit Azetylsalizyls\u00e4ure (ASS) und einem Thienopyridin (Ticlopidin = z.B. Tiklyd, Clopidogrel = Plavix, Iscover ) zur Prophylaxe einer Restenose empfohlen. In bestimmten Risikosituationen (z.B. akuter Myokardinfarkt, instabile Angina pectoris) wird zus\u00e4tzlich ein GP-IIb\/IIIa-Blocker (z.B. [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Unmittelbar vor und 3-4 Wochen nach einer koronaren Ballondilatation (Perkutane transluminale koronare Angioplastie = PTCA) mit Stent-Implantation wird heute eine Pharmakotherapie mit Azetylsalizyls\u00e4ure (ASS) und einem Thienopyridin (Ticlopidin = z.B. Tiklyd, Clopidogrel = Plavix, Iscover ) zur Prophylaxe einer Restenose empfohlen. In bestimmten Risikosituationen (z.B. akuter Myokardinfarkt, instabile Angina pectoris) wird zus\u00e4tzlich ein GP-IIb\/IIIa-Blocker (z.B. [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[1321,4890,5133,5134,2656,324,106],"class_list":["post-40290","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-eptifibatid","tag-esprit-studie","tag-gp-iib-iiia-rezeptor-antagonisten","tag-gp-iib-iiia-rezeptor-blocker","tag-koronar-stent","tag-stent","tag-thrombozytenaggregationshemmer"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Unmittelbar vor und 3-4 Wochen nach einer koronaren Ballondilatation (Perkutane transluminale koronare Angioplastie = PTCA) mit Stent-Implantation wird heute eine Pharmakotherapie mit Azetylsalizyls\u00e4ure (ASS) und einem Thienopyridin (Ticlopidin = z.B. Tiklyd, Clopidogrel = Plavix, Iscover ) zur Prophylaxe einer Restenose empfohlen. In bestimmten Risikosituationen (z.B. akuter Myokardinfarkt, instabile Angina pectoris) wird zus\u00e4tzlich ein GP-IIb\/IIIa-Blocker (z.B. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2001-03-01T11:05:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/03\/Abbildung-2001-21b-1.gif\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie\",\"datePublished\":\"2001-03-01T11:05:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/\"},\"wordCount\":617,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2001\\\/03\\\/Abbildung-2001-21b-1.gif\",\"keywords\":[\"Eptifibatid\",\"ESPRIT-Studie\",\"GP-IIb\\\/IIIa-Rezeptor-Antagonisten\",\"GP-IIb\\\/IIIa-Rezeptor-Blocker\",\"Koronar-Stent\",\"Stent\",\"Thrombozytenaggregationshemmer\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/\",\"name\":\"Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2001\\\/03\\\/Abbildung-2001-21b-1.gif\",\"datePublished\":\"2001-03-01T11:05:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2001\\\/03\\\/Abbildung-2001-21b-1.gif\",\"contentUrl\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2001\\\/03\\\/Abbildung-2001-21b-1.gif\",\"width\":250,\"height\":227},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/","og_locale":"de_DE","og_type":"article","og_title":"Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie - Der Arzneimittelbrief","og_description":"Unmittelbar vor und 3-4 Wochen nach einer koronaren Ballondilatation (Perkutane transluminale koronare Angioplastie = PTCA) mit Stent-Implantation wird heute eine Pharmakotherapie mit Azetylsalizyls\u00e4ure (ASS) und einem Thienopyridin (Ticlopidin = z.B. Tiklyd, Clopidogrel = Plavix, Iscover ) zur Prophylaxe einer Restenose empfohlen. In bestimmten Risikosituationen (z.B. akuter Myokardinfarkt, instabile Angina pectoris) wird zus\u00e4tzlich ein GP-IIb\/IIIa-Blocker (z.B. [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2001-03-01T11:05:00+00:00","og_image":[{"url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/03\/Abbildung-2001-21b-1.gif","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie","datePublished":"2001-03-01T11:05:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/"},"wordCount":617,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/03\/Abbildung-2001-21b-1.gif","keywords":["Eptifibatid","ESPRIT-Studie","GP-IIb\/IIIa-Rezeptor-Antagonisten","GP-IIb\/IIIa-Rezeptor-Blocker","Koronar-Stent","Stent","Thrombozytenaggregationshemmer"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/","name":"Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/#primaryimage"},"thumbnailUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/03\/Abbildung-2001-21b-1.gif","datePublished":"2001-03-01T11:05:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/#primaryimage","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/03\/Abbildung-2001-21b-1.gif","contentUrl":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2001\/03\/Abbildung-2001-21b-1.gif","width":250,"height":227},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/eptifibatid-bei-koronaren-stent-implantationen-die-esprit-studie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Eptifibatid bei koronaren Stent-Implantationen. Die ESPRIT-Studie"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40290","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40290"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40290\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40290"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40290"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40290"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}